| 2025-12-16 |
详情>>
内部人交易：
Estepan Ian Michael股份减少13187.00股
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本10478.72万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-4.37美元,归母净利润-4.31亿美元,同比去年增长-665.12%
|
| 2025-11-03 |
财报披露：
美东时间 2025-11-03 盘后发布财报
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益-2.57美元,归母净利润-2.51亿美元,同比去年增长-688.59%
|
| 2025-07-29 |
复牌提示：
2025-07-28 16:18:58 停牌，复牌日期 2025-07-28 17:40:00
|
| 2025-05-06 |
详情>>
业绩披露：
2025年一季报每股收益-4.6美元,归母净利润-4.48亿美元,同比去年增长-1338.98%
|
| 2025-04-24 |
股东大会：
将于2025-06-05召开股东大会
会议内容 ▼▲
- 1.To elect, as Class II directors to hold office until the 2027 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Richard J. Barry, M. Kathleen Behrens, Ph.D., Stephen L. Mayo, Ph.D., and Claude Nicaise, M.D.;
2.To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation;
3.To approve an amendment to the Company’s 2018 Equity Incentive Plan (as amended on April 3, 2020, April 5, 2022 and April 6, 2023) (the “2018 Plan”) to increase the maximum aggregate number of shares of the Company's common stock that may be issued pursuant to awards granted under the 2018 Plan by 4,300,000 shares to 17,487,596 shares;
4.To approve an amendment to the Amended and Restated 2013 Employee Stock Purchase Plan (as amended and restated on June 27, 2016, and amended on June 6, 2019 and on June 8, 2023) (the “2016 ESPP”) to increase the number of shares of the Company's common stock authorized for issuance under the 2016 ESPP by 300,000 shares to 1,700,000 shares;
5.To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2025;
6.To transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof.
|
| 2025-02-28 |
详情>>
业绩披露：
2022年年报每股收益-8.03美元,归母净利润-7.03亿美元,同比去年增长-67.99%
|
| 2025-02-28 |
详情>>
业绩披露：
2024年年报每股收益2.47美元,归母净利润2.35亿美元,同比去年增长143.89%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.80美元,归母净利润7619.00万美元,同比去年增长113.10%
|
| 2024-08-07 |
详情>>
业绩披露：
2023年中报每股收益-6.11美元,归母净利润-5.41亿美元,同比去年增长-60.68%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益0.45美元,归母净利润4257.90万美元,同比去年增长107.87%
|
| 2024-05-01 |
详情>>
业绩披露：
2024年一季报每股收益0.38美元,归母净利润3611.90万美元,同比去年增长106.99%
|
| 2024-04-24 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.To elect, as Class I directors to hold office until the 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Douglas S. Ingram, Hans Wigzell, M.D., Ph.D., Kathryn J. Boor, Ph.D. and Michael Chambers;
2.To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation;
3.To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2024;
4.To transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof.
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益-5.8美元,归母净利润-5.36亿美元,同比去年增长23.81%
|
| 2023-11-01 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-6.56美元,归母净利润-5.82亿美元,同比去年增长2.12%
|
| 2023-04-24 |
股东大会：
将于2023-06-08召开股东大会
会议内容 ▼▲
- 1.To elect, as Class II directors to hold office until the 2025 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Richard J. Barry, M. Kathleen Behrens, Ph. D., Stephen L. Mayo, Ph. D., and Claude Nicaise, M.D.;
2.To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation;
3.To approve an amendment to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 2,500,000 shares to 13,187,596 shares;
4.To approve an amendment to the Amended and Restated 2013 Employee Stock Purchase Plan (as amended and restated on June 27, 2016 and amended on June 6, 2019) (the “2016 ESPP”) to increase the number of shares of our common stock authorized for issuance under the 2016 ESPP by 300,000 shares to 1,400,000 shares;
5.To hold an advisory vote on whether an advisory vote on executive compensation should be held every one, two or three years;
6.To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2023;
7.To transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof.
|
| 2022-04-25 |
股东大会：
将于2022-06-02召开股东大会
会议内容 ▼▲
- 1.to elect, as Class I directors to hold office until the 2024 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Kathryn Boor, Ph.D., Michael Chambers, Douglas S. Ingram, and Hans Wigzell, M.D., Ph.D.;
2.to hold an advisory vote to approve, on a non-binding basis, named executive officer compensation;
3.to approve an amendment to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 2,500,000 shares to 10,687,596 shares;
4.to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2022;
5.to transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-20 |
股东大会：
将于2021-06-03召开股东大会
会议内容 ▼▲
- 1.to elect, as Class II directors to hold office until the 2023 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Richard J. Barry, M. Kathleen Behrens, Ph.D. and Claude Nicaise, M.D.;
2.to hold an advisory vote to approve, on a non-binding basis, named executive officer compensation;
3.to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2021;
4.to transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof.
|
| 2020-04-21 |
股东大会：
将于2020-06-04召开股东大会
会议内容 ▼▲
- 1.to elect, as Class I directors to hold office until the 2022 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Douglas S. Ingram, Hans Wigzell, M.D., Ph.D. and Mary Ann Gray, Ph.D.;
2.to hold an advisory vote to approve, on a non-binding basis, named executive officer compensation;
3.to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Restated Certificate”), to increase the number of authorized shares of common stock from 99,000,000 to 198,000,000 shares;
4.to approve, contingent upon the approval of Proposal 3, an amendment to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 3,800,000 shares to 8,187,596 shares;
5.to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2020;
6.to transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof.
|
| 2019-04-26 |
股东大会：
将于2019-06-06召开股东大会
会议内容 ▼▲
- 1.to elect, as Group II directors to hold office until the 2021 annual meeting of stockholders, or until their successors are earlier elected, the following nominees: Richard J. Barry, M. Kathleen Behrens, Ph.D. and Claude Nicaise, M.D.;
2.to hold an advisory vote to approve, on a non-binding basis, named executive officer compensation;
3.to approve an amendment to the Amended and Restated 2013 Employee Stock Purchase Plan (as amended and restated on June 27, 2016) (the “2016 ESPP”) to increase the number of shares of our common stock authorized for issuance under the 2016 ESPP by 500,000 shares to 1,100,000 shares and to extend its term until April 22, 2029;
4.to ratify the selection of KPMG LLP as our independent registered public accounting firm for the current year ending December 31, 2019;
5.to transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof. The accompanying Notice of Meeting and proxy statement describe these matters. We urge you to read this information carefully.
|
| 2018-04-26 |
股东大会：
将于2018-06-06召开股东大会
会议内容 ▼▲
- 1.to elect, as Group I directors to hold office until the 2020 annual meeting of stockholders, or until their successors are earlier elected, the following nominees: Michael W. Bonney, Douglas S. Ingram and Hans Wigzell, M.D., Ph.D.;
2.to hold an advisory vote to approve, on a non-binding basis, named executive officer compensation;
3.to approve the Company’s 2018 Equity Incentive Plan;
4.to ratify the selection of KPMG LLP as our independent registered public accounting firm for the current year ending December 31, 2018;
5.to transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof.
|
| 2017-04-27 |
股东大会：
将于2017-06-06召开股东大会
会议内容 ▼▲
- 1.to elect, as a Group II directors to hold office until the 2019 annual meeting of stockholders, or until their successors are earlier elected, the following nominees: Richard J. Barry, M. Kathleen Behrens, Ph.D. and Claude Nicaise, M.D.;
2.to hold an advisory vote to approve, on a non-binding basis, named executive officer compensation;
3.to hold an advisory vote on whether an advisory vote on executive compensation should be held every one, two or three years;
4.to ratify the selection of KPMG LLP as our independent registered public accounting firm for the current year ending December 31, 2017;
5.to transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof.
|
| 2016-05-31 |
股东大会：
将于2016-06-27召开股东大会
会议内容 ▼▲
- 1.to elect, as Group I director to hold office until the 2018 annual meeting of stockholders, or until his successor is earlier elected, the following nominee: Hans Wigzell, M.D., Ph.D.;
2.to hold an advisory vote to approve, on a non-binding basis, named executive officer compensation;
3.to approve an amendment and restatement of our Amended and Restated 2011 Equity Incentive Plan (the “Restated Plan”) to, among other changes, increase the number of shares underlying the awards that the Company may grant under the Restated Plan by 1,300,000 shares to 7,536,903 shares (plus the number of shares subject to outstanding awards under the 2002 Equity Incentive Plan that expire or otherwise terminate without having been exercised in full, or are forfeited to or repurchased by us, up to a maximum of 121,325 shares)(the “Restated Plan amendment and restatement”);
4.to approve an amendment and restatement to the 2013 Employee Stock Purchase Plan (the “2013 ESPP”) to increase the number of shares of our common stock authorized for issuance under the 2013 ESPP by 350,000 shares to 600,000 shares;
5.to ratify the selection of KPMG LLP as our independent registered public accounting firm for the current year ending December 31, 2016;
6.to transact such other business as may properly come before the Annual Meeting, or any continuation, postponement or adjournment thereof.
|